BofA lowered the firm’s price target on Lenz Therapeutics (LENZ) to $35 from $52 and keeps a Buy rating on the shares as the firm updated its model to incorporate preliminary Q4 net product revenue and early Vizz script trends. While the firm lowers its 2027-32 Vizz forecast by 25% on average, reflecting a slower launch ramp, it adds that it remains optimistic the recently initiated DTC ad campaign can drive an acceleration in Vizz uptake.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- LENZ Therapeutics: Early VIZZ Launch, Targeted DTC Campaign, and Differentiated Presbyopia Profile Underpin Buy Rating
- Lenz Therapeutics, Sarah Jessica Parker launch ‘Make it VIZZable’
- Robust Early Adoption, Favorable Safety Profile, and Upcoming DTC Campaign Support Buy Rating on VIZZ
- Lenz Therapeutics sees Q4 net product revenue $1.6M
- Lenz, Lunatus announce exclusive partnership for VIZZ in Middle East